Nirmal Bang: Dr. Reddy’s Target Price Revised On Lower gVascepa Estimate, Sputnik Vaccine
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
We revise our estimates on gVascepa sales for Dr. Reddy’s Laboratories Ltd. Last quarterly sales annualised for Vascepa are 620 million U.S. dollar.
We account for upside from Sputnik vaccine in the company’s target price considering the publication of positive data from interim analysis of phase three studies suggesting more than 95% efficacy at 21 days post administration of the second dose.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.